Bentham Science Logo

Track Your Manuscript:


Current Cancer Drug Targets

Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access

Meet the Executive Guest Editor(s)

Manny D. Bacolod
Department of Microbiology and Immunology
Weill Cornell Medical College
New York, NY
(USA)
Dr. Manny D. Bacolod is currently an Assistant Professor of Microbiology and Immunology at Weill Cornell Medical College (New York, NY). After earning his Ph.D. in Chemistry from the University of Connecticut, he has held various research positions at Duke University Medical Center, Weill Cornell Medical College, Brigham and Women’s Hospital, and Virginia Commonwealth University. Dr. Bacolod’s contribution to cancer literature encompasses a wide range of topics including colon cancer genomics and biomarker discovery, epigenetics, cancer genetics, brain tumor drug resistance, chemical mutagenesis, cancer metastasis, and immuno oncogenomics.


Yonghan He
Kunming Institute of Zoology
Kunming Institute of Zoology, Chinese Academy of Sciences
Kunming
(China)
Dr. Yonghan He received his M.D. degree from Harbin Medical University in China. He finished his post-doctoral training at the University of Arkansas for Medical Sciences, and University of Florida in the USA. He is presently serving as an Associate professor of Kunming Institute of Zoology, Chinese Academy of Sciences. Dr. He focuses on studying the mechanisms involved in cancer cell death, and developing small molecules or natural compounds that suppress tumor cell growth. He is also very interested in studying cellular senescence and developing senolytics that can selectively kill senescent cells to improve the health of aged individuals. Dr. He has published more than 50 peer-reviewed papers in journals related to cancer or aging.


Heiko Konig
Department of Hematology and Oncology
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, IN
(USA)
Dr. Heiko Konig is presently serving as an Assistant Professor at the Indiana University Melvin & Bren Simon Cancer Center in Indianapolis where his effort is dedicated to the care of patients with acute myeloid leukemia (AML) and other hematological malignancies, and laboratory based research with a focus on the role of hypoxia in the development of AML drug resistance and minimal residual disease. He received his MD and doctoral degrees from the medical schools at the Ludwig Maximilians University Munich and the Philipps University Marburg/ Germany, respectively. He is also serving as the co-chair of the Big Ten Cancer Research Consortium (BTCRC) Myeloid Malignancies Clinical Trial Working Group and the Hoosier Cancer Research Network (HCRN) Lymphoma/Leukemia Clinical Trial Working Group.


Yinghua Li
Guangzhou Women and Children’s MedicalCenter
Guangzhou Medical University
Guangzhou
(China)
Dr. Yinghua Li is currently serving as a professor in the Center laboratory, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China. He and his group members are currently interested in functionalized nanomaterials in anticancer and antivirus, Targeted drug delivery; siRNA for cancer treatment; Mechanisms of multidrug resistance; Apoptosis signal transduction; Anticancer and antivirus molecular mechanisms;. He has contributed more than 80 peer reviewed papers in international journals such as Nano Today, Redox Biology, Materials Today, Drug Delivery, Small, Journal of Biomedical science and Current Cancer Drug Targets.


Guangwei Liu
Institute of Cell Biology, College of Life Sciences
Beijing Normal University
Beijing
(China)
Dr. Guangwei Liu is currently serving as a professor in the Key Laboratory of Cell Proliferation and Regulation, Ministry of Education, Beijing Normal University, Beijing, China. He and his group members are currently interested in understanding the molecular and cellular mechanisms for positive and negative regulation of T cell immune function, exploring the possibility for clinical application of anti-tumor immunotherapy and anti-infection, as well as establishing protocols to induce transplant immune tolerance. He has contributed more than 70 peer reviewed papers in international journals such as Immunity, Nature Immunology, Nature Communications, PNAS, Blood, Journal of Immunology and Cancer Research.


Valery V. Tuchin
Department of Physics
Institute of Precision Mechanics and Control of the RAS
Saratov State University
Saratov
(Russia)
Dr. Valery V. Tuchin is presently serving as a Professor and Chair of Optics and Biophotonics at Saratov University (National Research University of Russia). He is also the head of Laboratory of Laser Diagnostics of Technical and Living Systems, Institute of Precision Mechanics and Control, RAS, and the supervisor of Interdisciplinary Laboratory of Biophotonics at Tomsk State University (National Research University of Russia) and Laboratory of FemtoMedicine of ITMO University (National Research University of Russia). His research interests include tissue optics, laser medicine, tissue optical clearing, and nanobiophotonics. He has published more than 700 papers (Web of Science), 27 monographs and text-books, and 58 book chapters. Dr. Tuchin is also a holder of more than 50 patents.


Junpu Wang
Department of Pathology
Xiang-ya Hospital
Changsha
(China)
Dr. Pu has been working in the Department of Pathology, Xiang-ya Hospital, Central South University since 2009. His main research topics are, basic and clinical research of gastrointestinal tumor pathology/Ultramicroscopic pathology/Mitochondrial encephalomyopathy. At present, more than 40 teaching and scientific research papers have been published, among them, multiple SCI papers have been published as the first author/corresponding author. Apart from that, has presided over more than 10 projects including the National Natural Science Foundation of China, the Postdoctoral Science Foundation of China, the Natural Science Foundation of Hunan Province (Youth and General project), and the Postgraduate and Undergraduate Education Reform Projects, and has obtained more than 20 national patents. Guest reviewer of several SCI journals. Besides, he is also a member of a number of societies such as Chinese Society of Pathology, Chinese Research Hospital Association, Member of Hunan Pathology Society, Committee member of Hunan Neuroscience Society etc. He has 16 publications to his credit.


Fanglong Wu
Department of General and Emergency Medicine
Sichuan University
Chengdu
(China)
Dr. Fanglong Wu, M.D., Ph.D. is an Associate professor in the Department of Oral Medicine and Department of General and Emergency Medicine, Sichuan University, Chengdu, China. He is also the Deputy Director in the Department of Conservative Dentistry and Oral Medicine, Sichuan University, Chengdu, China. He completed his Ph.D in Oral and Maxillofacial Surgery from 2012-2015, and another Ph.D in Oral Medicine from 2015-2018, both from Sichuan University, China. His interests and expertise are: Head and Neck Cancer, Tumor Immunology, Tumor Microenvironment, Cancer Targeted Therapy and TGF-beta Signal Transduction. He has 21 publications to his credit. In 2019, he delivered an invited lecture on “TGF-βRII regulates glucose metabolism in oral cancer-associated fibroblasts”, at the 4th Meeting of the International Association for Dental Research Asia Pacific Region, Speaker, Queensland, Australia.


Editor-in-Chief

Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
View Full Editorial Board

COPE Compliant

Cope Logo

Journal History

Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.

Advertisement

Mechanisms-of-Metabolic-Disorders-(MMD)

Related Journals

Related eBooks

eBooks Catalog